<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008068</url>
  </required_header>
  <id_info>
    <org_study_id>0012490</org_study_id>
    <nct_id>NCT05008068</nct_id>
  </id_info>
  <brief_title>Effect of Local Application of Platelet-rich Fibrin Scaffold Loaded With Simvastatin on Peri-implant Bone Changes</brief_title>
  <official_title>Effect of Local Application of Platelet-rich Fibrin Scaffold Loaded With Simvastatin on Peri-implant Bone Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British University In Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British University In Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACKGROUND: Simvastatin (SIM), a pharmacological drug used for hypercholesterolemia, has been&#xD;
      found to have pleotropic effects on bones. Simvastatin together with the appropriate carrier&#xD;
      may decrease bone loss around implants.&#xD;
&#xD;
      PURPOSE: To compare the long term effects of autologous PRF alone, and PRF loaded with SIM on&#xD;
      peri-implant bone changes and implant stability in patients undergoing implant&#xD;
      rehabilitation.&#xD;
&#xD;
      MATERIALS AND METHODS: A randomized controlled split-mouth studyincluding 8 males between the&#xD;
      ages of 45-60 years. Each patient received two implants, one on each side of the arch. One&#xD;
      side was treated with PRF alone and the other side with PRF +Simvastatin, at the time of&#xD;
      Osteotomy. A cone-beam CT was used to evaluate bone changes around the insertion of implant&#xD;
      sites atthree, six, and twelve months postoperatively. The secondary outcome included&#xD;
      measuring implant stability using Ostell device at baseline and 3 months post insertion. To&#xD;
      compare groups at different time periods, data was examined using a two-way (ANOVA) analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Actual">September 12, 2020</completion_date>
  <primary_completion_date type="Actual">September 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient received two implants, one on each side of the arch. One side was treated with PRF alone and the other side with PRF +Simvastatin, at the time of Osteotomy.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The measurement of bone thickness</measure>
    <time_frame>After 3 months of the osteotomy and application of Simvastatin</time_frame>
    <description>Measuring unit in millimeters , measuring device is CBCT software</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The measurement of bone thickness</measure>
    <time_frame>After 6 months of the osteotomy and application of Simvastatin</time_frame>
    <description>Measuring unit in millimeters , measuring device is CBCT software</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The measurement of bone thickness</measure>
    <time_frame>After 12 months of the osteotomy and application of Simvastatin</time_frame>
    <description>Measuring unit in millimeters , measuring device is CBCT software</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Platelet-rich Fibrin</condition>
  <condition>Simvastatin</condition>
  <arm_group>
    <arm_group_label>PRF alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PRF in addition to Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin with PRF at site of osteotome</description>
    <arm_group_label>PRF alone</arm_group_label>
    <arm_group_label>PRF in addition to Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with a partially edentulous mandible indicated for rehabilitation with&#xD;
             implant prostheses,&#xD;
&#xD;
          -  any extractions, or surgeries performed at least six months earlier.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with systemic diseases affecting bone quality or resorption&#xD;
&#xD;
          -  temporomandibular joint dysfunction,&#xD;
&#xD;
          -  severe attrition or parafunctional habits,&#xD;
&#xD;
          -  patients undergoing radiotherapy or chemotherapy,&#xD;
&#xD;
          -  heavy smokers,&#xD;
&#xD;
          -  vulnerable groups such as psychologically unstable patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The British University in EGYPT</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British University In Egypt</investigator_affiliation>
    <investigator_full_name>Sara Fikry El Shafei</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Platelet-rich fibrin</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Bone loss</keyword>
  <keyword>Peri-implant Bone Changes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

